BETHESDA, Md., May 20, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that its Chief Technical Officer, Dr. Marnix Bosch, will give a presentation on "Autologous Dendritic Cells for Glioblastoma" on Saturday, on May 21, at 1:45 pm at the 14th Annual Meeting of the American Society of Cell and Gene Therapy in Seattle, WA. Dr. Bosch's talk will take place in rooms 615-617 at the Washington State Convention Center.
Dr. Bosch will provide an update on NWBT's DCVax® -L therapeutic cancer vaccine for Glioblastoma multiforme ("GBM"), the most lethal form of brain cancer. DCVax® -L is in a Phase II, randomized, double blinded, placebo controlled clinical trial at multiple institutions. The trial is designed and powered at a level comparable to a pivotal study. Dr. Bosch's presentation will discuss the striking long-term follow-up data from prior trials, the design of this ongoing Phase II trial, and plans for further clinical development of DCVax®-L for brain cancer. The update will include discussion of the lack of toxicity, ease of administration, and other characteristics of the product and its clinical implementation that will make it suitable for widespread adoption in the medical community.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company is developing dendritic cell-based vaccines. The Company's lead clinical trial is its 240-patient Phase II trial in newly diagnosed GBM. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.
For further information about clinical sites and about the Company, please visit the Company's web site at www.nwbio.com.
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
|SOURCE Northwest Biotherapeutics|
Copyright©2010 PR Newswire.
All rights reserved